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Abstract
Background: With an ageing population and widening indications for pacemakers implantation, the number of
persons carrying an implant is steadily increasing. The routine follow-up is thus a heavy burden for the respective NHS
as well as for the patients and their relatives. Most of them of the studies have been performed in densely populated
areas and nearby to the hospital. It is thus unknown whether these results could be applied also in rural areas such as
Northern Norway with a more scattered population. The aim of this study was to assess the effectiveness of tele-
monitoring (TM) in patients with pacemakers regarding reliability, safety and health-related quality of life, compared to
traditional follow-up in outpatient clinic in a setting where geographical effects could possible influence the results.
Methods: The NORDLAND study is a controlled, randomized, non-masked clinical trial in pacemaker patients, with data
collection carried out during the pre-implant stage and after 6 months. Between August of 2014 and November of
2015, 50 patients were assigned to either a tele-monitoring group (n = 25) or a conventional hospital monitoring (HM)
group (n = 25). The EuroQol-5D (EQ-5D) utilities and visual analogue scale (VAS) and the Minnesota Living with Heart
Failure Questionnaire (MLHFQ) were used to measure Health-Related Quality of Life. Baseline characteristics and
number of hospital visits were also analyzed.
Results: The baseline characteristics of the two study groups were similar for EQ-5D utilities (TM:0.81; HM:0.76; p = 0.47)
, EQ-5D VAS (TM: 64.00; HM:64.88; p = 0.86) and the MLHFQ (TM:20.20; HM:28.96; p = 0.07). At the 6 month follow-up,
there were no significant differences between the groups in EQ-5D utilities (TM: 0.81; HM: 0.76; p = 0.54) and EQ-5D
VAS scores (TM: 72.71; HM: 59.79; p = 0.08). The MLHFQ score was improved in both groups (TM: -4.40; HM: -15.13;
p < 0.001). The number of in-office visits was similar in both groups (TM: 1.24 vs HM: 1.12; P = 0.30).
Conclusions: The NORDLAND trial shows that HRQoL is improved after implant in both groups. Without significant
differences with regards to effectiveness and safety. In addition, provides a scientifically rigorous method to the field of
HRQoL evaluations in patients with pacemakers.
Trial registration: ClinicalTrials.gov NCT02237404, September 11, 2014.
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Background
International guidelines of professional practice advises
that users with pacemakers (PM) must be monitored in
periods between 3 and 12 months [1, 2]. Every hospital
visit usually involves an assessment of pacemakers func-
tion, cardiovascular events and an analysis of patient phys-
ical status and, whether is necessary the medication is
modified and/or the device is re-configured again [1, 3].
With an ageing population and widening indications for PM
implantation, the number of persons carrying an implant is
steadily increasing. The routine follow-up is thus a heavy
burden for the respective national health services [4] as well
as for the pacemakers users and their caregivers [5, 6].
Remote monitoring or tele-monitoring (TM) systems
have potential advantages such as early detection of car-
diovascular events and early response to technical prob-
lems of the device or changes in the patient’s clinical
status [7–10]. TM may be a potential alternative to help
reduce the number of in-office visits to hospital, thereby
optimizing medical resources [11]. Along last decade, sev-
eral studies have showed that TM is as effective as trad-
itional follow-up in hospital [2, 10–13]. In addition, the
number of unscheduled visits to the hospital for assistance
at the emergency services and hospitalizations can be re-
duced [4, 14]. In the last decade a limited number of stud-
ies have shown results on efficiency [4, 7, 15, 16]
particularly based on patient-reported outcomes such as
HRQoL [10–12, 15–18]. On the other part, a study pub-
lished recently affirms that telemedicine is not signifi-
cantly more effective than usual care on mental and
physical Health-Related Quality of Life (HRQoL) [19].
However, the majority of these studies have not been ran-
domized, but have based their allocation to mode of
follow-up to patient or observer preference. Furthermore,
several of them have been performed in densely populated
areas with most of the patients living only a short distance to
the following centre. It is thus unknown whether these re-
sults apply also in a randomized study and in rural areas
such as Northern Norway with a more scattered population.
Regarding previous paragraph, there is no inter-
national standard for defining rural areas, and the exist-
ing ones may vary even within a same country [20, 21].
Previous publications indicate that the healthcare needs
of patients living in rural areas usually be different from
those in urban areas, and patients living in rural areas
often they tend to have problem access to healthcare
[22]. Nordland county (Norway) has a scattered popula-
tion of 6,3 inhab/sq. km (for comparison Canada has
3,7, USA 34,8 and United Kingdom 274 inhab/sq. km)
[20, 23]. Although a large fraction of the population in
Nordland county (Norway) lives in cities, the cities are
small and there is still a significant proportion of inhabi-
tants living in communities with less than 2500 individ-
uals and at distances a long way from the hospital.
The purpose of the present study was to assess the
effectiveness of TM in patients with pacemakers regard-
ing reliability, safety and health-related quality of life,
compared to traditional follow-up in outpatient clinic in




Controlled, randomized, non-masked clinical trial with
patient assignment to conventional follow-up in the
hospital or tele-monitoring follow-up by electronic data
transmission with 6 months monitoring from the date of
implantation.
The randomization process was performed as follows:
A person unrelated to the study prepared a total of 50
sealed envelopes, 25 which included at note reading “tel-
e-monitoring” and 25 with a note reading “hospital mon-
itoring”. The envelopes were thoroughly mixed and
numbered from 1 to 50. When a patient had accepted
the invitation to participate in the study and signed the
informed consent he was given a consecutive study
number and allocated to follow-up in accordance with
the specification included in the corresponding envelope.
Thus, the investigators had no knowledge of or influence
on the randomization result prior to inclusion.
Environment
The study was carried out in Nordland Hospital, Bodø,
Norway, a hospital with a pacemaker center that serves a
population of 170,000 inhabitants and performs around
80–90 pacemakers implants per year.
Participants and selection
All patients who were scheduled for implant with a pace-
maker between August of 2014 and October of 2015 and
met all the inclusion criteria (age 18 years or older, ability
to give informed consent and to operate the home moni-
tor, life expectancy > 1 year) and none of the exclusion cri-
teria (scheduled for implantable cardioverter-defibrillator
(ICD) or cardiac resynchronization therapy (CRT), partici-
pation in other trials) were invited to participate. A total
of 76 patients were screened and 50 patients were
included and randomized to either telemonitoring (TM,
n = 25) or hospital monitoring (HM, n = 25). No changes
to methods were performed after trial commencement.
Devices
According to their diagnosis, patients received either a single
(VVIR) or a dual chamber pacemaker (DDDR). Patients
assigned to tele-monitoring received either a Biotronik
Estella SR-T/ DR-T or a Biotronik Evia SR-T/ DR-T. Patients
assigned to hospital monitoring received either one of the
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aforementioned Biotronik pacemakers, a St Jude Medical
Endurity SR/DR or a Sorin Reply 200 SR/DR.
Home monitoring was performed through the Biotro-
nik Home Monitoring® system, an internet-based TM
service for users with Biotronik implantable heart de-
vices. Biotronik devices equipped with Home Monitor-
ing (T-devices) have additional storage capacity and
contain a small RF-antenna for wireless communication
and data transmission from the implant to a wireless pa-
tient device, the CardioMessenger. Home Monitoring
has no negative effects on devices’ battery life [24].
Every night, the CardioMessenger automatically col-
lects and transmits important, encrypted health informa-
tion to the Biotronik service center using the global
network of T-Mobile and its partners (GPRS). The trans-
mitted patient data is collected, automatically analyzed
and filtered at the Biotronik Home Monitoring Service
Center, according to patients‘needs as defined by their
physician. Health and system-related issues are ranked
and marked in order of importance. All event and trend
reports can be accessed and reviewed on a protected on-
line platform. Furthermore, according to pre-set defini-
tions, the physician can receive automatic warnings (e.g.
by e-mail or text message) concerning safety issues such
as premature battery depletion, lead fracture etc.
Primary outcome measures
HRQoL of the users with pacemakers was assessed
through the Norwegian version of the utility scores of
the EuroQol-5D (EQ-5D) [25] from − 1 [the worst state
of health] to 1 [the best state of health], and the
self-rated HRQoL was analyzed through of the EQ-5D
Visual Analogue Scale (EQ-5D-VAS), from 0 [worst im-
aginable health state or death] to 100 [perfect health]).
Secondary outcome measures
To measure the effects of symptoms, functional limita-
tions and psychological reactions commonly associated
with heart failure or its treatment on an individual’s
quality of life, the Norwegian validated version of the
MLHFQ. It consists of 21 questions regarding patients’
perception of the effects of HF on their daily lives; the
score for each question ranges from 0 to 5, producing a
total score of 0 to 105, with a higher score indicating a
poorer HRQoL [26–29].
Other outcome measures
Differences between TM and HM groups, in regards to:
1) Cardiovascular events (AE), including exitus, percu-
taneous coronary intervention, angina and lead dislodge-
ment 2) monitoring visits and transmissions from home
vs. hospital and 3) changes of medication and pace-
makers reprogramming.
Follow-up
Patients were given 3 interviews (on the day of the pace-
makers implant, and at 1 and 6 months after the im-
plant) in which the corresponding questionnaires were
administered. These interviews were carried out in a
personalized way during hospitalization or by telephone
interviews after discharge.
To ensure that the sample size was representative, due
to the limited capacity of patient enrolment in the hospi-
taI, the following formula was used: n¼ N :Z2:pð1−pÞðN−1Þe2þZ2:pð1−pÞ
Thus, from a target population of n = 70, assuming a
standard deviation of Z = 1.96, with a margin of error e
= 0.10, a proportion of p = 0.5, and a 10% of possible
losses, we got a size sample necessary of n = 45. We did
not have any prior information on the value that was ex-
pected to be found. For this reason, 50% has been used
as the statistical power (p = 0.5) meaning that, if there
was any effect, it would be detected at the 50% of the
total events.
Statistical analysis
Continuous variables were assessed as mean ± standard
deviation. Categorical data in both groups were com-
pared using difference in proportions test (binomial
method) or Chi-Square test or Fisher exact test, when
was appropriated. Differences between both groups were
also assessed in the pre-specified endpoints using the
difference in means or proportions tests and Wilcoxon
signed ranks test for Minnesota Living with Heart Fail-
ure Questionnaire. Results are presented, including the
corresponding 95% confidence intervals (95% CI). All
statistical analyses were performed with SPSS (SPSS In-
stitute, Inc., Chicago, IL, USA) statistical software.
Results
Participants
Between August of 2014 and October of 2015, 50 pa-
tients (mean age: 75 ± 12 years, 48% women) were en-
rolled in the NORDLAND study, of which 25 were
included in the TM group and 25 in the HM group
(Fig. 1). Dizziness was the most common symptom, and
the patients were most commonly referred from the hos-
pital’s own cardiology ward or from other local hospitals.
The most common pacing indication was sick sinus syn-
drome (48%) followed by atrioventricular block (40%). In
88% of the cases, DDDR pacemakers were used. Hyper-
tension was the most frequent comorbidity (64%). None
of the baseline characteristics, including HRQoL were
different between the two groups (Table 1).
Health-related quality of life basal analysis
In basal analysis patients had a mean score of 0.78
(95%CI:0.72;0.85) for EQ5D utilities and 64.83 (95%
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CI:56.74;70.14) for EQ5D VAS, which was increased to
0.81 (95%CI: -0.75;0.87) and 67.80 (95%CI: 62.49;73.10)
respectively at 1 month after PM implantation (Table 2).
Changes between baseline and 1 month EQ5D utilities
and VAS were not statistically significant (p = 0.81 and
p = 0.20, respectively). TM and HM groups showed no
significant differences in EQ5D utilities and VAS scores be-
tween enrollment and at month (Table 2), nor at any EQ5D
utilities dimensions. Regarding MLHFQ, the patients had a
mean score at baseline of 24.58 (95%CI:19.30;29.86). This
improved significantly to 16.55 (95%CI:11.40–21.70) at the
1 month assessment (p < 0.05). There were no significant
differences in MLHFQ scores between TM and HM groups
(20.20 vs. 28.96; p = 0.07) at baseline or at 1 month of
follow-up (18.64 vs. 14.38, p = 0.59) (Table 3).
Cardiovascular adverse events and workload
After 6 months of follow-up, 6% of patients had experienced
at least one AE (TM: 6%, HM: 4.2%; p = 0.40) (Table 4).
After PM implantation, 38.2% of patients were hospitalized
at least once (TM: 42%, HM: 33.4%; p = 0.55). The main
causes of hospitalization were due to coronary problems
(TM, 16% vs. HM, 20.8%) and PM dysfunction (TM, 12%
vs. HM, 0%), however no significant differences between the
groups were found. One patient (HM group) died for
non-cardiovascular causes. As for workload, a mean of 1.20
± 0.50 in-hospital visits per patient were registered during
the follow-up period (TM:1.24 vs. HM:1.17; p = 0.26).
Health related quality of life results at 6 months
At 6 months, the EQ5D utilities score (Table 5) was in-
creased to 0.79 (95%CI: 0.71;0.86; p = 0.54), 0.01 points
more than baseline and 0.02 points less than the scores
reached in month 1 (95% CI: -0.16;0.10; p = 0.64). On the
EQ-5D VAS, the mean score reached 66.74 points, 1.91
points higher than in basal analysis (relative increase of
2.86%; p = 0.42) and 1.06 points less than the obtained in
month 1 after implant (relative decrease of 1.59%; p = 0.72).
The MLHFQ scores (Table 5) revealed a significant im-
provement for both groups (− 9.65 points; 95% CI: 9.04–
20.02), with significant differences compared to baseline
scores (p < 0.001) and 2.02 points less than the obtained
at month 1 after implant (reduction of 12.21%; P = 0.39).
At the end of the study period, HM group experienced
the better response with respect to month 0 (TM: − 4.4 vs.
HM: − 15.75). At 6 months, there were no significant dif-
ferences between the two groups (TM: 15.80 versus HM:
13.21; p = 0.97).
Fig. 1 Flow (CONSORT) diagram of the study
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Discussion
Principal findings
Among the main results of the NORDLAND study,
we found that, a) there was not significant differences
in HRQoL assessed through EQ-5D utilities and VAS
questionnaires administered at 1 and 6 months after
implant between users included in the two groups of
follow-up, b) in MLHF questionnaire were found sig-
nificant differences in both groups between the enrol-
ment and the end of follow-up period, c) safety was
similar between both groups and no significant differ-
ences were found, d) that number of visits to hospital
Table 1 Patients’ demographic and clinical characteristics at baseline
All (n = 50) Groups P-
valueTM (n = 25) HM (n = 25)
Age (mean) ± SD 74.84 ± 11.8 73.68 ± 14.2 76.00 ± 8.8 0.68
Men (mean) 26 (52.0) 13 (52.0) 13 (52.0) 1.00
MLHFQ [95CI] 24.58 [19.30;29.86] 20.20 [14.48;25.92] 28.96 [19.97–37.95] 0.07
EQ5D utilities [95CI] 0.78 [0.72;0.85] 0.81 [0.74;0.87] 0.76 [0.64;0.88] 0.47
Pacing indication (%)
Sick sinus syndrome 24 (48.0) 12 (48.0) 12 (48.0) 0.65
Atrioventricular block 20 (40.0) 11 (44.0%) 9 (36.0)
Chronic AF with Bradycardia 6 (12.0) 2 (8.0) 4 (16.0)
Disease manifestations (%)
Syncope 14 (28.0) 8 (32.0) 6 (24.0) 0.81
Dizziness 25 (50.0) 12 (48.0) 13 (52.0)
Dyspnoea 11 (22.0) 5 (20.0) 6 (24.0)
Service derivated (%)
Emergency dept. 3 (6.0) 1 (4.0) 2 (8.0) 0.51
Cardiology ward 14 (28.0) 5 (20.0) 9 (36.0)
Primary healthcare 4 (8.0) 2 (8.0) 2 (8.0)
Other hospitals 29 (58.0) 17 (68.0) 12 (48.0)
Stimulation (%)
DDDR 44 (88.0) 23 (92.0) 21 (84.0) 0.33
VVIR 6 (12.0) 2 (8.0) 4 (16.0)
Comorbidities (%)
Dislipidemia 27 (54.0) 13 (52.0) 14 (56.0) 0.50
Obesity (BMI > 30) 1 (2.0) 0 (0.0) 1 (4.0) 0.50
Tachyarrhythmia 18 (36.0) 7 (28.0) 11 (44.0) 0.19
Hypertension 32 (64.0) 17 (68.0) 15 (60.0) 0.38
Diabetes Mellitus 6 (12.0) 0 (0.0) 6 (24.0) 0.01
Other comorbidities (%)
None 18 (36.0) 11 (44.0) 7 (28.0) 0.39
Others 10 (20.0) 6 (24.0) 4 (16.0)
Coronary heart diseases 22 (44.0) 8 (32.0) 14 (56.0)
Pharmaceutical treatment (%)
Antiaggregants 18 (36.0) 8 (32.0) 10 (40.0) 0.38
Anticoagulants 25 (50.0) 10 (40.0) 15 (60.0) 0.13
Antiarrhythmics 18 (36.0) 7 (28.0) 11 (44.0) 0.19
Antihypertensives 32 (64.0) 18 (72.0) 14 (56.0) 0.19
N = 50 (Telemonitoring group: 25; Hospital Monitoring group: 25). Values are expressed as means or proportions. 95CI: 95% confidence interval of means; AF atrial
fibrillation, BMI body mass index, EQ5D EuroQoL-5D, DDD bicameral pacemaker with two electrodes placed in the atrium and in the ventricle with the ability to
modulate frequency of stimulation, MLHFQ Minnesota Living with Heart Failure, VVIR unicameral pacemaker with an electrode in the ventricle with the ability to
modulate frequency of stimulation
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for both groups was similar and no significant differ-
ences were found.
Health-related quality of life
Several studies [10, 16–18, 30] have assessed HRQoL in
users with pacemakers. In these clinical trials, the SF-36
[16, 17, 30] and EQ5D [10, 18] questionnaires were used
to assess HRQoL. Results were improved but no signifi-
cant differences between both groups in either the ef-
fectiveness or the safety of TM and HM were found.
Coinciding with previous trials [16, 17, 30] there was not
found significant improvement in health-related quality of
life for both groups between the enrolment and the last
month of the study. In other more recent studies [17, 18],
users with pacemaker implants included in both groups re-
ported significant improvements in HRQoL assessed
through the EQ-5D [10] and SF-36 [18]. On the other
hand, in NORDLAND study the MLHF questionnaire
score was improved in the studied groups (21.78% vs.
54.42%) and at 6 months there were statistically significant
differences between the groups. These results were similar
to those obtained in other studies in which HRQoL ques-
tionnaires for specific heart-diseases such as MLHFQ [30],
AQUAREL [18], Duke Activity Status Index (DASI) [10]
were improved. In all the studies, similar results have been
found regardless their research design, either randomized
or non-randomized.
Safety of tele-monitoring of pacemaker users
Previous studies [7, 10, 17, 30] showed a reduction in
the percentage of in-office follow-up visits (31 to 58%).
These results contrast with the obtained in the NORD-
LAND study where the visits to the hospital were 2%
higher in TM group with respect to the other group
(TM:1.24 vs. HM:1.17; p = 0.26). Additionally, in NORD-
LAND study, there were 98 transmissions scheduled for
home patient (TM group) plus 10 extra ones (unsched-
uled transmissions).
Table 3 Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores at 6 months














Swelling in ankles, legs 0.84 1.00 0.72 0.50 0.58 0.88 0.25 0.42 0.57
Rest during the day 1.28 2.08 0.13 1.29 1.08 0.75 1.08 0.88 0.69
Walking and climbing stairs 0.96 1.92 0.09 0.96 0.54 0.41 0.63 0.63 0.96
Working around the house 1.20 2.36 0.03 0.96 1.25 0.61 0.50 1.13 0.18
Going away from home 0.28 1.44 0.01 0.92 0.21 0.06 0.79 0.83 0.92
Sleeping 0.84 1.32 0.27 0.71 0.71 0.94 0.58 0.50 0.83
Doing things with
friends or family
0.88 1.96 0.04 1.04 0.71 0.42 1.04 0.83 0.68
Working to earn a living 0.40 0.72 0.23 0.50 0.08 0.14 0.00 0.04 0.32
Recreational pastimes 1.24 1.76 0.23 1.29 0.88 0.39 1.21 1.17 0.92
Sexual activities 0.32 0.68 0.31 0.25 0.42 0.52 0.71 0.67 0.96
Eat less of the food liked 0.60 1.00 0.21 0.71 0.42 0.36 0.50 0.17 0.34
Shortness of breath 2.44 2.48 0.99 1.46 1.04 0.32 1.29 1.50 0.60
Fatigue, tireness, low on energy 2.36 3.20 0.08 1.54 1.38 0.76 1.38 1.38 0.97
Stay in the hospital 1.48 1.76 0.58 1.00 1.38 0.55 0.58 0.38 0.60
Costing money for medical care 0.60 0.80 0.50 0.71 0.42 0.19 0.25 0.13 0.85
Side effects from medication 0.44 0.68 0.47 0.13 0.83 0.06 0.54 0.79 0.53
Feeling burdensome 0.32 0.76 0.19 0.46 0.08 0.12 0.21 0.21 0.71
Feeling a loss of self control 0.80 0.76 0.95 0.54 0.46 0.72 0.42 0.38 0.92
Worry 1.00 0.88 0.64 0.79 0.67 0.81 0.67 0.38 0.41
Difficulty remembering &
concentrating
1.16 0.96 0.53 1.00 0.75 0.59 0.92 0.54 0.37
















TM: Tele-monitoring group; HM: Hospital monitoring group; N (month 0) = 50 (TM group: 25; HM group: 25). N (month 1) = 49 (TM group: 25; HM group: 24). N
(month 6) = 49 (TM group: 25; HM group: 24). Items values are expressed as means. Total values are expressed as means [95CI: 95% confidence interval of means]
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Table 4 Follow-up information at 6 months
Total N (%) Tele-monitoring N (%) Hospital Monitoring N (%) P-value
Number of transmissions from consultation room
0 0 (0.0) 0 (0.0) 0 (0.0) 0.26
1 41 (83.7) 21 (84.0) 20 (83.3)
2 6 (12.2) 2 (8.0) 4 (16.7)
3 2 (4.1) 2 (8.0) 0 (0.0)
Transmissions from patients home
0 29 (59.2) 5 (20.0) 24 (100) < 0.001
3–5 15 (30.6) 15 (60.0) 0 (0.0)
6–8 5 (10.2) 5 (20.0) 0 (0.0)
Extra transmissions from patients home
0 45 (91.8) 21 (84.0) 24 (100) 0.12
1 1 (2.0) 1 (4.0) 0 (0.0)
3 3 (6.2) 3 (12.0) 0 (0.0)
Cardiovascular adverse events
None 46 (93.9) 23 (92.0) 23 (95.8) 0.40
PCI 1 (2.0) 1 (4.0) 0 (0.0)
Angina 1 (2.0) 0 (0.0) 1 (4.2)
Lead dislodgement ×2 1 (2.0) 1 (2.0) 0 (0.0)
Changes of medication
0 33 (67.3) 17 (68.0) 16 (66.7) 0.11
1 7 (14.3) 5 (20.0) 2 (8.3)
2 3 (6.1) 1 (4.0) 2 (8.3)
3 4 (8.2) 0 (0.0) 4 (16.7)
4 2 (4.1) 2 (8.0) 0 (0.0)
Changes of pacemakers reprogramming
0 34 (69.4) 16 (64.0) 18 (75.0) 0.34
1 13 (26.5) 7 (28.0) 6 (25.0)
2 2 (4.1) 2 (8.0) 0 (0.0)
Hospitalizations days after implant
0 30 (61.2) 14 (56.0) 16 (66.7) 0.55
1 14 (28.6) 7 (28.0) 7 (29.2)
2 4 (8.2) 3 (12.0) 1 (4.2)
5 1 (2.0) 1 (2.0) 0 (0.0)
Days hospitalizated
0 30 (61.2) 14 (56.0) 16 (66.7) 0.54
1–5 12 (24.5) 6 (24.0) 6 (25.1)
6–10 4 (8.1) 2 (8.0) 2 (8.4)
+ 10 3 (6.0) 3 (12.0) 0 (0.0)
Reasons for hospitalization
None 30 (61.2) 14 (56.0) 16 (66.7) 0.37
Others 6 (12.3) 3 (12.0) 3 (12.5)
Cancer 1 (2.0) 1 (4.0) 0 (0.0)
Coronary problems 9 (18.4) 4 (16.0) 5 (20.8)
PM disfuction 3 (6.1) 3 (12.0) 0 (0.0)
TM tele-monitoring group, HM hospital monitoring group, N (month 6) = 49 (TM group: 25; HM group: 24). Items values are expressed as N (%). PCI
percutaneous coronary intervention, PM pacemakers



































































































































































































































































































































































































































































































































































Lopez-Villegas et al. BMC Geriatrics  (2018) 18:223 Page 9 of 12
The results on early detection of cardiovascular events
and safety were similar to those obtained in previous
studies [10, 16, 17, 31–35]. There were no found signifi-
cant differences among the two groups with regards to
cardiovascular events. The cumulative number of cardio-
vascular events was slightly higher in the TM (6%) than
in the HM group (4.2%) although no statistically signifi-
cant differences were found. This is relevant since it has
been demonstrated that either a high burden of atrial
fibrillation can be an important predictor of stroke and
even mortality [5, 11, 13]. On the other hand, results
found in previous studies showed that users included in
TM group were more satisfied, the number of in-office
visits to hospital was reduced, feeling safer, and being
closely monitored by competent health care profes-
sionals with negligible impact of tasks to be fulfilled to
comply with monitoring [5, 18, 36, 37] and although the
number of studies on HRQoL and costs performed up
to present on telemonitoring of pacemakers is quite re-
duced, preliminary studies suggest costs-saving [15]. A
very reduced number of studies on effectiveness in pace-
makers telemonitoring have used the HRQoL (EQ5D
and SF-36) [10, 16, 17] questionnaires.
The added value of the NORDLAND study
To our knowledge, the NORDLAND study is the first ran-
domized clinical trial (RCT) evaluating HRQoL in the
tele-monitoring of users with pacemakers. The RCT is the
most scientifically rigorous method of hypothesis testing
available [38], and is regarded as the gold standard trial for
evaluating the effectiveness of interventions [39]. Therefore,
the NORDLAND study provides an important input for fu-
ture systematic reviews and clinical decision-making with
regards to the use of tele-monitoring of users with pace-
makers. In addition, to our knowledge, the NORDLAND
study is first using the Minnesota Living with Heart Failure
Questionnaire, which offers an innovative approach in the
field of internet-based health technologies assessments.
Strengths and limitations
Despite the relevant results obtained, the study has some
limitations. First, it is a trial where patients and health
staff knew the type of monitoring assigned, possibly this
aspect may have influenced in their behavior. However,
such influence has been decreased as much as possible
since the NORDLAND study is a randomized trial. This
ensures major evidence level, less chance of bias due to
random selection of the groups and it might be repeat-
able and comparable with other studies. Second, the
final size of patients included in this trial (with a limited
number of pacemakers implants per year) made it
difficult to detect differences between the two groups.
The lack of a larger final sample size and the limited
differences between groups may have reduced the real
statistical power. However, the proximity between the re-
sults found in both groups in the analyses performed do
not indicate significant differences. In addition, our study
is a single centre study which may also be an advantage as
different clinical practice among different hospitals some-
times makes it difficult to conduct multicenter studies.
Moreover, the comparison and generalization of re-
sults to other settings may be supported as participant
characteristics were quite similar to those reported in
previous studies [2–7, 10, 16, 17] in terms of age, gender,
symptoms and indications.
Finally, it must be considered the phenomenon known
as the Hawthorne effect [40, 41]. The fact that people
tend to change their behavior when they are the targets
of interest and attention, regardless of the specific nature
of an intervention could be a limitation of our results. In
such situations, patients become eager to please their
physicians and make them feel successful. Additionally,
patients wish to participate so that “good” results can be
achieved in the study [40, 41].
Conclusions
To conclude, data obtained in the NORDLAND study
show that health-related quality of life in patients with
pacemakers is improved 6 months after implant in both
groups. No significant differences between tele-monitoring
and in-office follow-up groups were found with regards to
effectiveness in terms of health-related quality of life, feasi-
bility, reliability, safety and number of visits to hospital. Fi-
nally, this randomized clinical trial provides a scientifically
rigorous method to the field of health-related quality of
life evaluations in users with pacemakers.
Future research in this area should focus on interventions
based on quality of life perceived by the patients and costs
of multi-center studies involving a long-term follow-up of
users with the telemonitoring of pacemakers and other
types of cardiovascular implantable electronic devices.
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